drugset / Trial / NCT01533389

Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones

NCT01533389

Phase 4 Completed 114 enrolled JW Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

A lower ureteral calculus, which measures 5 millimeters and less, may be easily expelled by symptomatic therapy. Actually, it has about a 50% chance of successful expulsion. However, a complication such as urinary tract infection or hydronephrosis or persistent pain may occur before it is expelled. Thus, it is imperative to minimize the occurrence of complications in the process of expectant treatment and also to reduce the time required to expel calculi. Pharmacotherapy is to relieve ureteral obstruction and thus to expel urinary calculi easily. This clinical trial is to evaluate the efficacy of silodosin, a selective α1A-blocker, on calculous expulsion in expectant treatment for patients with lower and mid ureteral calculi.

Timeline

Start
2011-10
Primary completion
2012-03
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Silodosin Unknown 8 mg

Indications